UNSPSC 51433201: Ambrisentan

This classification denotes an endothelin-1 protein receptor antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HW6NV07QEC. European Medicines Agency schedules Ambrisentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25424. Ambrisentan generally arises in the molecular formula C22H22N2O4.

The term AMBRISENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule ambrisentan under HS 29335995 and SITC 51576. As of Q4 2014, AMBRISENTAN remains the US FDA Preferred Term for this commodity. Ambrisentan bears US NLM identifiers UMLS ID C1176329 and NCI Concept Code C72694. SMILES: O(C(C(Oc1nc(cc(n1)C)C)C(=O)O)(c1ccccc1)c1ccccc1)C.

UNSPSC 51433201 Ambrisentan, a Commodity code, describes a specific endothelin-receptor antagonist pharmaceutical used in the treatment of pulmonary arterial hypertension. State and local governments procure ambrisentan and related advanced life support medications through emergency services departments, public health agencies, and cooperative purchasing alliances that supply hospitals, fire rescue services, and state health and human services programs. The recent procurement activity shows that state and local buyers are sourcing medications through sealed-bid competitions for emergency medical supplies, direct-to-manufacturer pharmacy initiatives, and multistate cooperative purchasing agreements that aggregate demand across dozens of jurisdictions and authorized wholesalers. Issuing bodies include city purchasing departments acting on behalf of fire and rescue services, state health and human services commissions, and multistate cooperative purchasing alliances administering procurement on behalf of participating state and local facilities.

Recent activity spans Florida, Texas, and Minnesota-led multistate cooperatives. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including epinephrine, adenosine, diltiazem, and labetalol for Tampa Fire Rescue, with an estimated contract value of $40,000, a one-year term with optional renewals, and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, with awarded vendors effective July 1, 2026, and performance penalties for contract violations. Contract terms typically run one to two years with renewal options, and vendors must maintain FDA compliance, comprehensive insurance coverage, and expiration dates meeting minimum shelf-life requirements.